2. Search Result
Search Result
Results for "

HIV isolates

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

4

Peptides

1

Inhibitory Antibodies

1

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111964
    Lenacapavir
    Maximum Cited Publications
    19 Publications Verification

    GS-6207

    		 HIV Infection
    Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir
  • HY-17040
    Darunavir
    15+ Cited Publications

    TMC114; UIC-94017

    		 HIV HIV Protease Infection Inflammation/Immunology
    Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity .
    Darunavir
  • HY-15148
    Tipranavir
    10+ Cited Publications

    PNU-140690

    		 HIV Protease HIV SARS-CoV Infection
    Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL pro activity .
    Tipranavir
  • HY-120072
    PF-3450074
    5 Publications Verification

    PF-74

    		 HIV Infection
    PF-3450074 (PF-74) is a specifical inhibitor of HIV-1 capsid protein (CA) and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC50=8-640 nM). PF-3450074 (PF-74) acts at an early stage of HIV-1 infection, inhibits viral replication by directly competing with the binding of CPSF6 and NUP153, and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle . CPSF6: nuclear host factors cleavage and polyadenylation specific factor 6; NUP153: nucleoporin 153.
    PF-3450074
  • HY-120427
    Cosalane
    1 Publications Verification

    NSC 658586

    		 CCR CXCR HIV HSV Infection Inflammation/Immunology
    Cosalane (NSC 658586) is a CCR7 (IC50 = 2.43 μM) and CXCR2 antagonist (IC50 = 0.66 μM). Cosalane is an inhibitor of HIV replication with a wide range of activity against HIV-1 isolates, HIV-2, Rauscher murine leukemia virus, HSV-1, HSV-2 and human cytomegalovirus. Cosalane inhibits both attachment of gp120 to CD4. Cosalane inhibits human and murine CCR7 in response to both CCL19 and CCL21 agonists. Cosalane can be studied in research for HIV or attenuating acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) .
    Cosalane
  • HY-159828
    Dezecapavir

    VH-499; VH4011499

    		 HIV Infection
    Dezecapavir (VH-499) is a HIV-1 capsid protein inhibitor. Dezecapavir exhibits picomolar-level antiviral activity against a variety of HIV-1 laboratory strains and clinical isolates in vitro. Dezecapavir inhibits the early and late stages of the HIV-1 life cycle, blocking nuclear import, reverse transcript production, virion assembly, maturation, and post-nuclear import/pre-integration replication processes. Dezecapavir can be used in studies related to HIV-1 infection .
    Dezecapavir
  • HY-111964A
    Lenacapavir sodium
    Maximum Cited Publications
    19 Publications Verification

    GS-6207 sodium

    		 HIV Infection
    Lenacapavir (GS-6207) sodium is an HIV-1 capsid inhibitor. Lenacapavir sodium binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir sodium exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir sodium is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir sodium
  • HY-122470
    Stampidine

    		Reverse Transcriptase HIV Infection
    Stampidine is a nucleoside reverse transcriptase inhibitor (NRTI) with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain HTLVIIIB (B-envelope subtype) and primary clinical isolates with IC50s of 1 nM and 2 nM, respectively. Stampidine also inhibits NRTI-resistant primary clinical isolates and NNRTI-resistant clinical isolates with IC50s of 8.7 nM and 11.2 nM, respectively .
    Stampidine
  • HY-107123
    TMC310911
    1 Publications Verification

    ASC-09

    		 HIV Protease Infection
    TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC50 values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1. TMC310911 has potent activity against a wide spectrum of recombinant HIV-1 isolates. TMC310911 has strong antiviral activity .
    TMC310911
  • HY-103078
    I-XW-053

    		HIV Reverse Transcriptase Infection
    I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection .
    I-XW-053
  • HY-106395
    Telinavir

    SC-52151

    		 HIV Protease HIV Infection
    Telinavir (SC-52151) is a potent and selective HIV protease inhibitor. Telinavir inhibits lymphotropic, monocytotropic strains and field isolates of HIV type 1 (HIV-1), HIV-2, and simian immunodeficiency virus with EC50s of 26 ng/mL (43 nM). Telinavir is highly protein bound in human plasma and exhibits low partitioning into erythrocytes .
    Telinavir
  • HY-14891
    Fosdevirine

    GSK2248761; FDV

    		 HIV Reverse Transcriptase Infection
    Fosdevirine (GSK2248761) is is a potent, selective, non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1) replication with low nanomolar activity in vitro. Fosdevirine shows good activity against a broad range of HIV-1 strains, including efavirenz (HY-10572)-resistant clinical isolates .
    Fosdevirine
  • HY-13053
    Depulfavirine
    1 Publications Verification

    Ro-0335

    		 Reverse Transcriptase Cancer
    RO-0335 is a novel and potent diphenylether nonnucleoside reverse transcriptase inhibitor(NNRTI). RO-0335 inhibits Wt HIV-1 with an IC50 of 1.1 nM and retained activity (IC50< 100 nM) against 92% of a large number of NNRTI-resistant clinical isolates .
    Depulfavirine
  • HY-106395A
    (Rac)-Telinavir

    (Rac)-SC-52151

    		 HIV Protease HIV Infection
    (Rac)-Telinavir ((Rac)-SC-52151) is a racemate of Telinavir (HY-106395A). Telinavir (SC-52151) is a potent and selective HIV protease inhibitor. Telinavir inhibits lymphotropic, monocytotropic strains and field isolates of HIV type 1 (HIV-1), HIV-2, and simian immunodeficiency virus with EC50s of 26 ng/mL (43 nM). Telinavir is highly protein bound in human plasma and exhibits low partitioning into erythrocytes .
    (Rac)-Telinavir
  • HY-P4020
    2F5 epitope

    		HIV Others
    2F5 epitope, a peptide gp41 (659-671), comprises the entire epitope for one of the three known antibodies capable of neutralizing a broad spectrum of primary HIV-1 isolates and is the only such epitope that is sequential. 2F5 epitope is recognized by broadly neutralizing antibodies 2F5 .
    2F5 epitope
  • HY-103078A
    I-XW-053 sodium

    		HIV Reverse Transcriptase Infection
    I-XW-053 sodium is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 sodium disrupts capsid function and reduces polymerization levels. I-XW-053 sodium effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 sodium can be widely used in studies related to HIV-1 infection .
    I-XW-053 sodium
  • HY-15884
    GSK2838232

    		HIV Infection
    GSK2838232 inhibit HIV reverse transcriptase activity across a broad panel of HIV-1 isolates, extracted from patent WO/2013090664A1, compound51.
    GSK2838232
  • HY-P10517
    Sifuvirtide

    SFT

    		 HIV Infection
    Sifuvirtide (SFT) is a potent HIV fusion inhibitor. Sifuvirtide inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide can be used in the research of anti-HIV drugs .
    Sifuvirtide
  • HY-P991479
    Amtabafusp alfa

    GS-8588

    		 HIV CD3 Infection
    Amtabafusp alfa (GS-8588) is an envelope-targeting bispecific T-cell engager for HIV treatment. Amtabafusp alfa redirects effector T cells by binding to CD3 via a humanized anti-CD3 Fab domain and to HIV envelope proteins via an engineered CD4 domain 1 variant. Amtabafusp alfa exhibits potent, broad-spectrum activity against a variety of HIV isolates and specifically kills HIV-infected cells. Amtabafusp alfa can be used for research on HIV infection .
    Amtabafusp alfa
  • HY-17040R
    Darunavir (Standard)

    TMC114 (Standard); UIC-94017 (Standard)

    		 HIV HIV Protease Reference Standards Infection Inflammation/Immunology
    Darunavir (Standard) is the analytical standard of Darunavir. This product is intended for research and analytical applications. Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity .
    Darunavir (Standard)
  • HY-P10517A
    Sifuvirtide acetate

    SFT acetate

    		 HIV Infection
    Sifuvirtide (SFT) acetate is a potent HIV fusion inhibitor. Sifuvirtide acetate inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide acetate can be used in the research of anti-HIV drugs .
    Sifuvirtide acetate
  • HY-122256
    L-870812

    		HIV Integrase Infection
    L-870812 is a HIV-1 integration with integrase strand transfer inhibitor. L-870812 consistently blocks cell-free and cell-associated HIV-1 infection. L-870812 blocks subtype C and CRFO2_AG primary isolates. L-870812 can be used for the study of replication-deficient HIV-1 Ba-L (env) pseudovirus .
    L-870812
  • HY-P10653
    C5A

    		HCV HIV Infection
    C5A is a microbicidal peptide, anti-hepatitis C virus (HCV), and anti-HIV agent. C5A disrupts the membrane integrity of the HIV virion as well as the integrity of the conical capsid core that surrounds the viral genome. C5A inhibits in vitro infectivity of a broad range of primary HIV isolates in various primary target cells. C5A protects mice against vaginal and rectal HIV challenges .
    C5A
  • HY-15148S1
    Tipranavir-d7

    PNU-140690-d7

    		 HIV Protease HIV SARS-CoV Isotope-Labeled Compounds Infection
    Tipranavir-d7 is deuterated labeled Tipranavir (HY-15148). Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL pro activity .
    Tipranavir-d7
  • HY-15148R
    Tipranavir (Standard)

    PNU-140690 (Standard)

    		 Reference Standards HIV Protease HIV SARS-CoV Infection
    Tipranavir (Standard) is the analytical standard of Tipranavir. This product is intended for research and analytical applications. Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL pro activity .
    Tipranavir (Standard)
  • HY-105097
    Atevirdine mesylate

    U 87201E mesylate

    		 HIV Reverse Transcriptase Inflammation/Immunology
    Atevirdine (U 87201E) mesylate is a nonnucleoside reverse transcriptase (NNRT) inhibitor. Atevirdine mesylate can inhibit human immunodeficiency virus type 1 (HIV-1) with an IC50 of 0.06-1.6 μM. Atevirdine mesylate shows highly synergistic effects against Zidovudine/Didanosine-resistant clinical isolates of HIV-1 companied with Zidovudine (HY-17413)/Didanosine (Hy-B0249). Atevirdine mesylate can be used for the research of AIDS .
    Atevirdine mesylate
  • HY-112585
    Darunavir-d9

    TMC114-d9; UIC-94017-d9

    		 HIV HIV Protease Infection Inflammation/Immunology
    Darunavir-d9 (TMC114-d9) is the deuterium labeled Darunavir. Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity .
    Darunavir-d9
  • HY-122058
    KRH-3955

    		HIV Infection
    KRH-3955 is a CXCR4 antagonist with good bioavailability and potent anti-HIV-1 activity. KRH-3955 can effectively inhibit the replication of X4 HIV-1, including clinical isolates from different donors. KRH-3955 also shows activity against recombinant X4 HIV-1 containing reverse transcriptase, protease and tyrosinase resistance mutations. KRH-3955 can inhibit the binding of SDF-1alpha to CXCR4 and calcium ion signaling through this receptor. KRH-3955 inhibits the binding of an antibody against CXCR4 to CXCR4, showing a potent antagonistic effect on CXCR4. KRH-3955 shows an oral bioavailability of 25.6% in rats and can inhibit the replication of X4 HIV-1 in vivo .
    KRH-3955
  • HY-182678
    L-731988

    		HIV Integrase Infection
    L-731988 is an inhibitor targeting HIV-1 integrase. L-731988 inhibits HIV-1 replication by blocking integrase function. L-731988 exhibits ED50 values ranging from 0.5 μM to 3.14 μM against various HIV-1 isolates. L-731988 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
    L-731988
  • HY-182316
    P-1946

    		HIV Protease HIV Infection
    P-1946 is a HIV protease inhibitor with a human HIV-1 protease Ki of 2.600 nM. P-1946 has potent and selective in vitro antiviral activity and retains full antiviral activity against HIV isolates resistant to commercially available protease inhibitors. P-1946 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
    P-1946
  • HY-19281
    DMP-851

    		HIV Protease HIV Infection
    DMP-851 is a cyclic urea HIV protease inhibitor, with a Ki of 0.021 nM. DMP-851 shows antiviral activity against laboratory strains of HIV-l and HIV-2 as well as against primary clinical isolates derived from Zidovudine (HY-17413)-resistant samples (A018C, E, WR 10983) .
    DMP-851
  • HY-107123R
    TMC310911 (Standard)

    ASC-09 (Standard)

    		 Reference Standards HIV Protease Infection
    TMC310911 (Standard) (ASC-09 (Standard)) is the analytical standard of TMC310911 (HY-107123). This product is intended for research and analytical applications. TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC50 values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1. TMC310911 has potent activity against a wide spectrum of recombinant HIV-1 isolates. TMC310911 has strong antiviral activity .
    TMC310911 (Standard)
  • HY-N17982
    Vanillic acid 4-O-β-D-glucopyranoside

    		HIV Integrase Infection
    Vanillic acid 4-O-β-D-glucopyranoside is a vanillic acid glycoside with moderate antioxidant activity. Vanillic acid 4-O-β-D-glucopyranoside scavenges DPPH free radicals and superoxide anion radicals, and inhibits AAPH-induced lipid peroxidation in the linoleic acid system. The IC50 value of Vanillic acid 4-O-β-D-glucopyranoside against HIV-1 integrase is >100 μg/mL, indicating that it is not an effective HIV-1 integrase inhibitor. Vanillic acid 4-O-β-D-glucopyranoside is isolable from the ethyl acetate extract of Gardeniae Fructus.
    Vanillic acid 4-O-β-D-glucopyranoside
  • HY-103078R
    I-XW-053 (Standard)

    		Reference Standards HIV Reverse Transcriptase Infection
    I-XW-053 (Standard) is the analytical standard of I-XW-053 (HY-103078). This product is intended for research and analytical applications. I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection .
    I-XW-053 (Standard)
  • HY-182277
    GSK-1264

    		HIV Integrase HIV Infection
    GSK-1264 is an HIV-1 integrase inhibitor. GSK-1264 binds to a site spanning the HIV-1 integrase catalytic core domain and C-terminal domain, mediates formation of an open polymer of HIV-1 integrase dimers via inhibitor-bridged contacts between adjacent dimers. GSK-1264 disrupts late-stage HIV replication by interfering with viral particle assembly. GSK-1264 stimulates inappropriate polymerization of HIV-1 integrase. GSK-1264 can be used for the research of HIV infection .
    GSK-1264

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: